BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

25 Aug 2025 04:30:00 By Nasdaq GlobeNewswire

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

05 Aug 2025 13:01:00 By Nasdaq GlobeNewswire

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

23 Jul 2025 04:30:00 By Nasdaq GlobeNewswire

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

22 Jul 2025 04:30:00 By Nasdaq GlobeNewswire

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

30 Jun 2025 04:30:00 By Nasdaq GlobeNewswire

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

26 Jun 2025 04:30:00 By Nasdaq GlobeNewswire

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

02 Jun 2025 04:30:00 By Nasdaq GlobeNewswire

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

20 May 2025 04:30:00 By Nasdaq GlobeNewswire

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

19 May 2025 09:33:39 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 May 2025 13:01:00 By Nasdaq GlobeNewswire

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

13 May 2025 04:30:00 By Nasdaq GlobeNewswire

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

12 May 2025 04:30:00 By Nasdaq GlobeNewswire

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

07 May 2025 04:30:00 By Nasdaq GlobeNewswire

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

29 Apr 2025 13:01:00 By Nasdaq GlobeNewswire

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

28 Apr 2025 02:00:00 By Nasdaq GlobeNewswire

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

22 Apr 2025 04:30:36 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11 Apr 2025 13:01:00 By Nasdaq GlobeNewswire

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

31 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

27 Mar 2025 04:00:00 By Nasdaq GlobeNewswire

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

24 Mar 2025 04:30:00 By Nasdaq GlobeNewswire